Dupont Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Dupont Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,608	Closed	-$117K	–	1803
2021 Q4	$117K	Buy	+3,608	New	+$127K	﹤0.01%	1264
2021 Q2	–	Sell	-1	Closed	–	–	1867
2021 Q1	$0	Hold	1	–	–	﹤0.01%	1672
2020 Q4	$0	Sell	1 -39,998	-100%	-$520K	﹤0.01%	1430
2020 Q3	$418K	Buy	+39,999	New	+$422K	0.01%	839

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Dupont Capital Management's CERE Position: Q1 2022 in Review

Dupont Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022, closing a stake of 3,608 shares — an estimated $117K sold.

Dupont Capital Management first reported a position in CERE in Q3 2020 and held it in 4 quarters. The position peaked at $418K in Q3 2020. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

Dupont Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Dupont Capital Management sold 3,608 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $117K.
Dupont Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
Dupont Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $418K in Q3 2020.
107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.